{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:55:18Z","timestamp":1787993718877,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.prp.2020.153090","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T04:19:08Z","timestamp":1593404348000},"page":"153090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology"],"prefix":"10.1016","volume":"216","author":[{"given":"Raquel","family":"Machado-Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Eloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-1681","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Pol\u00f3nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2020.153090_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PAP.0b013e3182026d72","article-title":"HER2 testing in gastric cancer","volume":"18","author":"Albarello","year":"2011","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.prp.2020.153090_bib0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00129039-200403000-00003","article-title":"HER-2\/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components","volume":"12","author":"Andersson","year":"2004","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.prp.2020.153090_bib0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2020.153090_bib0020","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of american pathologists, american society for clinical pathology, and american society of clinical oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2020.153090_bib0025","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2020.153090_bib0030","first-page":"283","article-title":"Mixed gastric carcinomas show similar chromosomal aberrations in both their diffuse and glandular components","volume":"28","author":"Carvalho","year":"2006","journal-title":"Cell Oncol"},{"key":"10.1016\/j.prp.2020.153090_bib0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/PAT.0000000000000082","article-title":"High concordance rate of HER2 status assessed via silver in situ hybridisation (SISH) between core biopsy and excision specimens: a 4 year retrospective review from a single institution","volume":"46","author":"Chou","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2020.153090_bib0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00428-019-02567-z","article-title":"What to expect from the 2018 ASCO\/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?","volume":"475","author":"Curado","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2020.153090_bib0045","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2020.153090_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2020.153090_bib0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","article-title":"Intratumoral heterogeneity of HER2\/neu in breast cancer--a rare event","volume":"13","author":"Hanna","year":"2007","journal-title":"Breast J."},{"key":"10.1016\/j.prp.2020.153090_bib0060","article-title":"HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: chinese results of the HER-EAGLE study","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2020.153090_bib0065","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2020.153090_bib0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s10120-012-0150-9","article-title":"HER2 expression and its clinicopathological features in resectable gastric cancer","volume":"16","author":"Kataoka","year":"2013","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prp.2020.153090_bib0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.pathol.2017.05.009","article-title":"HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program","volume":"49","author":"Kumarasinghe","year":"2017","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2020.153090_bib0080","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ejca.2012.10.018","article-title":"Clinical significance of intratumoral HER2 heterogeneity in gastric cancer","volume":"49","author":"Lee","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2020.153090_bib0085","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2559.2011.04017.x","article-title":"Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections","volume":"59","author":"Lee","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2020.153090_bib0090","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05387-6","article-title":"HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor","author":"Liu","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2020.153090_bib0095","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2147\/CMAR.S188622","article-title":"State of the art for gastric signet ring cell carcinoma: from classification, prognosis, and genomic characteristics to specified treatments","volume":"11","author":"Machlowska","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.prp.2020.153090_bib0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000368555","article-title":"Clinicopathological features and prognostic significance of HER2 expression in gastric cancer","volume":"88","author":"Park","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.prp.2020.153090_bib0105","first-page":"397","article-title":"Are biopsy specimens predictive of HER2 status in gastric cancer patients?","volume":"58","author":"Pirrelli","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.prp.2020.153090_bib0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00428-016-1903-3","article-title":"Application of the 2013 ASCO\/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment","volume":"468","author":"Polonia","year":"2016","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2020.153090_bib0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-017-2189-9","article-title":"Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization","volume":"471","author":"Polonia","year":"2017","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2020.153090_bib0120","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1172\/JCI60534","article-title":"Heterogeneity in breast cancer","volume":"121","author":"Polyak","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2020.153090_bib0125","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2016.66.6693","article-title":"HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of american pathologists guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2020.153090_bib0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1746-1596-8-76","article-title":"HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population","volume":"8","author":"Shan","year":"2013","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.prp.2020.153090_bib0135","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2020.153090_bib0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12876-015-0231-4","article-title":"Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer","volume":"15","author":"Stahl","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.prp.2020.153090_bib0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gie.2019.03.022","article-title":"A survival guide to HER2 testing in gastric\/gastroesophageal junction carcinoma","volume":"90","author":"Subasinghe","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.prp.2020.153090_bib0150","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2128","article-title":"Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer","volume":"10","author":"Tamimi","year":"2008","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.prp.2020.153090_bib0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2020.153090_bib0160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.prp.2020.153090_bib0165","first-page":"1417","article-title":"Effect of HER-2\/neu over-expression on prognosis in gastric cancer: a meta-analysis","volume":"12","author":"Wang","year":"2011","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2020.153090_bib0170","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.humpath.2013.12.010","article-title":"Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status","volume":"45","author":"Wang","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2020.153090_bib0175","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical Oncology\/College of american pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2020.153090_bib0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00428-014-1597-3","article-title":"Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma","volume":"465","author":"Yoshida","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2020.153090_bib0185","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00428-007-0572-7","article-title":"Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas","volume":"452","author":"Zheng","year":"2008","journal-title":"Virchows Arch."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033820315193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033820315193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:45:24Z","timestamp":1759733124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033820315193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0344033820315193"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2020.153090","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2020.153090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153090"}}